A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab BR Followed by Rituximab vs Bortezomib-BR BVR Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT01216683

Study #:
STUDY00147143

Start Date:
Jun 28, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT01216683

View Complete Trial Details & Eligibility at ClinicalTrials.gov